Evidence map›Paper›PMID 40622519›Full record

ArticleJournal of endocrinological investigation2025

Causes of death among patients with metastatic differentiated thyroid cancer.

Q Liu, B Ma, M Song, H Sun, H Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Q LiuDepartment of Thyroid Surgery, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang, 110001, Liaoning, China.
B MaDepartment of Clinical Epidemiology and Evidence-Based Medicine, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang, 110001, Liaoning, China.
M SongDepartment of Thyroid Surgery, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang, 110001, Liaoning, China.
H Sun *Department of Clinical Epidemiology and Evidence-Based Medicine, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang, 110001, Liaoning, China. ivy_071602@126.com.
H Zhang *Department of Thyroid Surgery, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang, 110001, Liaoning, China. haozhang@cmu.edu.cn.ORCID http://orcid.org/0000-0002-9938-8433

Funding

Applied Basic Research Program of Liaoning Province 2022020225-JH2/1013Science and Technology Project of Shenyang City 21-173-9-31
6 · The paper itself

Abstract

backgroundNotwithstanding the generally positive outlook for differentiated thyroid cancer (DTC), metastatic differentiated thyroid cancer (mDTC) remains a lethal disease. In light of the current insufficient information regarding mortality causes in mDTC, our research endeavored to elucidate the factors contributing to death in patients diagnosed with mDTC. MATERIALS AND

methodsA cohort of 187,747 differentiated thyroid cancer (DTC) cases was extracted from the Surveillance, Epidemiology, and End Results-17 cancer registry database (2000-2020) and identified 4749 patients diagnosed with mDTC. The study estimated the cumulative mortality associated with thyroid cancer, subsequent cancers, and non-cancer-related causes. Standardized mortality ratios (SMR) were employed to evaluate the disparities between observed and expected mortality rates in mDTC patients.

resultsIn the DTC cohort, with a median follow-up of 70 months, 17,582 patients (9.4%) succumbed during the follow-up period. In the mDTC cohort, 2046 deaths (43.1%) occurred, with the 5-year cumulative mortality being highest for brain and liver metastases at 53.1% and 49.0%, respectively. During follow-up, 7.1% of patients with mDTC expired from subsequent cancers, with the largest proportion attributed to lung cancer. During the mDTC period, the most prevalent cause of non-cancer mortality was cerebrovascular diseases (SMR, 1.45; 95% CI, 1.05-1.94).

conclusionsNon-cancer-related mortality constitutes a substantial proportion of mDTC and exhibits an increasing trend. Enhanced attention should be directed toward the management of mDTC survivors, with individualized treatment and follow-up plans tailored to patient-specific factors, while providing comprehensive guidance regarding potential future health risks.

Indexed as

Thyroid NeoplasmsAdultAgedCause of DeathFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm MetastasisPrognosisRegistriesSEER ProgramSurvival RateYoung AdultCauses of deathObservational studyPrognosisStandard mortality ratioThyroid cancer

Identifiers

PMID40622519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.